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the effects of vitamin D deficiency have been recognised for 
centuries. however, it is a historical accident that vitamin D 
was classified as a vitamin, as vitamin D3 (cholecalciferol) is a 
fat soluble steroid hormone. Dietary vitamin D is absorbed in the 
small intestine and can be obtained from fish oils, liver, eggs, 
margarine and some dairy products. however, for most people 
at most times, synthesis of vitamin D in the skin is the most 
important source. it has been suggested that sunscreen use may 
interfere with vitamin D synthesis, but local data suggest that 
during an Australian summer sufficient sunlight is received by 
regular sunscreen users to produce vitamin D.1
 
Vitamin D promotes calcium and phosphate absorption by the 
small intestine, mineralisation of the skeleton and maintenance of 
extracellular calcium levels. Severe vitamin D deficiency may result 
in rickets or osteomalacia, rarely seen in modern Australia. However, 
osteoporosis and the consequent increased fracture risk can also 
result from vitamin D deficiency. 
 There are several new areas of interest in vitamin D. Vitamin D 
receptors are virtually ubiquitous in human tissue, and so perhaps not 
surprisingly, vitamin D deficiency has been linked with cancer mortality 
(colon, prostate, breast, ovary, pancreas), increased risk of autoimmune 
disease, abnormal lung function (including chronic obstructive pulmonary 
disease), tuberculosis, disorders of glucose metabolism, and psychiatric 
illness.2 More tenuous associations have been proposed with detrusor 
instability, swallowing disorders and age related macular degeneration. 
Epidemiologic observational studies suggest associations, but do not 
prove causality, and further study is ongoing.3–5  
Who is at risk?
Certain individuals are at increased risk of vitamin D deficiency, 
the most widely recognised being the elderly, especially those in 
residential care institutions.6 This is largely due to immobility resulting 
in limited sunlight exposure, and is exacerbated by the reduced ability 
of elderly skin to synthesise vitamin D even when exposed to sunlight. 
Background 
Vitamin D is essential for the normal functioning of a diverse range of 
metabolic processes, especially bone health. It is widely appreciated 
that the elderly are at increased risk of vitamin D insufficiency, but it 
is less well known that people with intellectual disability are also at 
increased risk. 
Objective
This article summarises the issues regarding vitamin D in people with 
intellectual disability, making recommendations about screening, 
management and follow up. 
Discussion 
The prevalence of intellectual disability in the Australian population 
has been estimated at just over 1%, implying that most general 
practitioners will care for several people with intellectual disability. 
Relatively simple steps are likely to have a significant impact on the 
health of this vulnerable group of people.
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People with intellectual disability
It is less well known that people with intellectual disability (ID) are 
also at high risk of vitamin D deficiency, with local studies suggesting 
a prevalence of 50–60% in this group.7 It is likely that the most 
important factor is reduced mobility. Time constraints of carers may 
limit the opportunities for people with ID to be exposed to sunlight, as 
may concerns over the hazards of excessive exposure.
 Reduced mobility is compounded by the association between 
anticonvulsant use and reduced vitamin D levels. Epilepsy prevalence 
may be as high as 26% in people with ID, and difficulties with seizure 
control make polypharmacy more likely.8 There is some evidence 
that the older anticonvulsants (eg. phenytoin, phenobarbitone) are 
more likely to be implicated, and that use of multiple anticonvulsant 
medications is more problematic than monotherapy.9
 People with ID have an increased risk of falls for many reasons, 
eg. reduced balance and coordination associated with the underlying 
cause of ID such as the spasticity associated with cerebral palsy,10 
and visual impairment, which affects up to 20% of people with 
ID.11 Vitamin D deficiency has been shown to be associated with an 
increased risk of falls due to effects on muscle, and if prolonged and 
severe, can cause a true myopathy.12
 Other conditions with a negative effect on bone health also occur 
in people with ID. The prevalence of coeliac disease, which causes 
calcium malabsorption, is increased in people with Down syndrome.13 
Hypogonadism, which increases the risk of osteoporosis, is also more 
common in Down syndrome and ubiquitous in Turner syndrome.14,15 
Women with ID may be long term users of depot progesterone only 
contraceptives, both for menstrual control and contraception.16 Such 
preparations have been associated with reduced bone density, and 
although it appears that this is largely reversible after cessation in 
short to medium term users, the effects in long term users are not 
clearly defined.17 It is important in all such individuals to be aware of 
these possible effects on bone health.
 The fracture rate in people with ID appears to be higher than 
that of the general population. Australian studies involving both 
community dwelling and institutionalised participants have found it to 
be 2–4 times higher;7,15,18 consistent with the international literature.7
skin synthesis of vitamin D 
Where possible, it is probably best to promote adequate skin 
synthesis of vitamin D via sunlight exposure. Table 1 details suggested 
sunlight exposure times for different geographic locations. These 
recommendations19 attempt to balance the need for vitamin D 
synthesis with the known harmful effects of ultraviolet light, but as yet 
have not been substantiated by formal trials. It is likely that time spent 
outdoors, especially if combined with mobility and exercise, will have 
the beneficial effects of an enriched lifestyle above and beyond the 
simple production of vitamin D. 
testing of vitamin D levels 
Given the high prevalence of vitamin D deficiency, routine testing of 
25-hydroxyvitamin D (25D) levels is appropriate in most, if not all, 
people with ID. There is broad agreement that 25D levels should 
exceed 50 nmol/L,20 with some suggesting that a threshold level of 
60–70 nmol/L may be more appropriate.2 Seasonality is important, 
especially in the more mobile, with levels tending to be at their lowest 
in late winter/early spring, and peaking in late summer/early autumn.6
 If vitamin D deficiency is found and treated, or the dose of an 
established treatment is altered, 25D levels should be checked 3–4 
months later. A further check 12 months later should be sufficient 
to guarantee adequate levels in the future, unless there is a change 
in health or lifestyle status. There is no published evidence base for 
these recommendations; they were derived by expert consensus with 
an understanding of the underlying physiology. 
supplementation 
Where adequate sunlight exposure is not possible or has not 
resulted in adequate 25D levels, supplementation should be used. 
Vitamin D3 is preferable to vitamin D2, as it appears to be more 
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Table 1. Recommended sun exposure by location and season16
 December – January July – August
Cairns (QLD) 6–7 mins 9–12 mins
Brisbane (QLD) 6–7 mins 15–19 mins
Perth (WA) 5–6 mins 20–28 mins
Sydney (NSW) 6–8 mins 26–28 mins
Adelaide (SA) 5–7 mins 25–38 mins
Melbourne (VIC) 6–8 mins 32–52 mins
Hobart (TAS) 7–9 mins 40–47 mins
Auckland (NZ) 6–8 mins 30–47 mins
Christchurch (NZ) 6–9 mins 49–97 mins
Note: This table assumes the following: moderately fair complexion, 
exposure of the face and either the arms or legs, exposure before 10 
am or after 2 pm (during daylight saving: before 11 am or after 3 pm)
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effective.21 Fracture prevention studies in the elderly suggest a 
dose of at least 800 IU/day in combination with adequate calcium 
(at least 1000 mg/day) is likely to be effective.22,23 For example, 
two tablets daily of Ostelin Vitamin D + Calcium would achieve this 
aim, at a cost of about $0.30 per day. Where moderate to severe 
deficiency is found, higher doses may be necessary for a period 
of time to normalise levels rapidly. While objective evidence is 
limited, a regimen of 4000 IU/day for 3–4 months may be required 
to achieve this. Reports of vitamin D toxicity are scarce, and have 
not been reported with doses of 4000 IU/day.2 Even 600 000 IU as 
an annual intramuscular ‘megadose’ is well tolerated.24 Toxicity 
cannot be caused by excessive sun exposure. Hypercalcaemia 
is the only contraindication to vitamin D supplementation, 
and calcium levels should be checked before supplementation. 
Although the literature is not entirely consistent, it is generally 
held that vitamin D should be given in combination with calcium, 
either through a suitable diet, or as a supplement. Regrettably, 
vitamin D supplementation is not funded by the Pharmaceutical 
Benefits Scheme.
conclusion 
From being thought of as an endocrine hormone principally affecting 
bone, calcium and phosphate, vitamin D has become the subject of 
speculation and investigation in relation to a range of physiological 
processes and disease states. It is likely that a significant number 
of Australians with ID are vitamin D deficient. Greater awareness 
and more assertive management will have significant health and 
economic benefits to this group of people. 
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